MediStem is dedicated to commercialization of the Endometrial Regenerative Cell (ERC), a universal donor stem cell product that does not require matching with the recipient. ERC have the ability to become brain, lung, liver, bone, cartilage, pancreatic, fat, muscle, heart, and blood vessel tissue.
MediStem has discovered and filed patents on a novel type of stem cell, the Endometrial Regenerative Cell (ERC). This cell appears to have all the major attributes desirable in an ideal cellular therapy: a) Grows well and is scalable for mass production; b) Can be administered intravenously because it selectively homes to damaged tissue; c) Does not require matching with the recipient, allowing for generation of standardized batches that can be shipped to the point of care.